{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:30:56Z","timestamp":1793982656214,"version":"4.8.0"},"reference-count":4,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Thyroid\u00ae"],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"\n Background:<\/jats:title>\n Developed by members of the American Thyroid Association (ATA) Clinical Affairs Committee, this executive summary of the 2025 ATA guidelines for adult patients with differentiated thyroid cancer provides a summary of key points and recommendations with an emphasis on notable differences between the 2025 and 2015 guidelines.<\/jats:p>\n <\/jats:sec>\n \n Summary:<\/jats:title>\n The updated guidelines emphasize individualized care through the DATA framework (Diagnosis, risk\/benefit Assessment, Treatment decisions, and response Assessment) with the goal of enhancing shared decision-making and personalized care. Highlights include expanded role of molecular diagnostics, refined risk stratification, greater emphasis on active surveillance and lobectomy, inclusion of ablative procedures, and selective use of external beam radiation therapy and chemoradiotherapy. De-escalation of surveillance for low-risk patients and introduction of the concept of complete remission are also new.<\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n This executive summary aims to provide a summary of key points and recommendations with an emphasis on notable differences between the 2025 and 2015 guidelines.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/10507256251390877","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:46:34Z","timestamp":1761554794000},"page":"1214-1220","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":15,"title":["Executive Summary of the 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer"],"prefix":"10.1177","volume":"35","author":[{"given":"Stephanie Smooke","family":"Praw","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Gigliotti","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Tessnow","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Internal Medicine, Southwestern Medical Center, University of Texas, Dallas, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunseok","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stanford University, Palo Alto, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra J.","family":"Margulies","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Summit Health, Morristown, New Jersey, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2015.0020"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/10507256251363120"},{"key":"e_1_3_2_4_2","volume-title":"Endocrine and Neuroendocrine Tumours","author":"WHO Classification of Tumours Editorial Board","year":"2025","unstructured":"WHO Classification of Tumours Editorial Board. Endocrine and Neuroendocrine Tumours, 5th ed. International Agency for Research on Cancer: Lyon, France; 2025. (WHO classification of tumours series, vol. 10).","edition":"5"},{"key":"e_1_3_2_5_2","volume-title":"AJCC Cancer Staging Manual","author":"Tuttle M","year":"2017","unstructured":"Tuttle M, , Haugen B, , Shah J, et al. Thyroid-differentiated and anaplastic carcinoma. In: AJCC Cancer Staging Manual, 8th ed. (Amin MB, , Greene F, , Byrd DR, eds.) Springer International: New York, NY; 2017.","edition":"8"}],"container-title":["Thyroid\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10507256251390877","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10507256251390877","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10507256251390877","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:11:12Z","timestamp":1787065872000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10507256251390877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":4,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,1]]}},"alternative-id":["10.1177\/10507256251390877"],"URL":"https:\/\/doi.org\/10.1177\/10507256251390877","relation":{},"ISSN":["1050-7256","1557-9077"],"issn-type":[{"value":"1050-7256","type":"print"},{"value":"1557-9077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]}}}